Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
28 mars 2023 06h52 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
24 mai 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
17 juin 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
19 juil. 2019 11h15 HE
|
Retrotope
LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
18 sept. 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as...
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
27 sept. 2017 07h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
08 juin 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
23 août 2016 10h15 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...